What are the main types of hematologic malignancy?

They are broadly the leukemias (cancers of blood-forming cells), the lymphomas (cancers of lymphoid tissue, divided into Hodgkin and non-Hodgkin types), and plasma-cell neoplasms such as multiple myeloma; each is further classified by lineage and genetics.

Why are blood cancers classified by genetics rather than location?

Because they arise from blood and lymphoid cells that circulate or are widely distributed, anatomic site is less informative than cell lineage and defining molecular or cytogenetic changes, which is what standardized classifications use to define disease entities.

Hematologic Malignancies

Hematologic malignancies are cancers of the blood, bone marrow, and lymphatic system, encompassing the leukemias, lymphomas, and plasma-cell neoplasms such as multiple myeloma. Unlike most solid tumors they often arise in circulating or diffusely distributed cells, are classified largely by cell lineage and genetics, and have been at the forefront of targeted and immune-based therapy.

Definition

Hematologic malignancies are neoplasms arising from cells of the blood-forming (myeloid) or lymphoid systems, classified by cell lineage, maturation stage, and molecular and cytogenetic features into leukemias, lymphomas, and plasma-cell and related disorders.

Scope

This topic provides an overview of the major categories of blood cancers, the lineage- and genetics-based classification used to define them, their general epidemiology, and the principles of treatment, including landmark targeted and immune therapies. It is a reference orientation to a large and heterogeneous group of diseases and their evidence base, not individualized clinical advice.

Core questions

How are blood cancers classified by lineage, maturation, and genetics?
Why have hematologic malignancies been pioneers of targeted and immune therapy?
How do acute and chronic, and myeloid and lymphoid, categories differ in behavior?
How do standardized classifications (e.g., WHO) structure diagnosis and evidence?

Key concepts

Myeloid versus lymphoid lineage
Acute versus chronic leukemia
Lymphomas (Hodgkin and non-Hodgkin)
Plasma-cell neoplasms (multiple myeloma)
Cytogenetics and molecular classification (e.g., BCR-ABL, WHO categories)
Targeted therapy and immunotherapy in blood cancers

Mechanisms

Hematologic malignancies arise when blood-forming or lymphoid cells acquire genetic alterations that disrupt normal differentiation, proliferation, and survival. They are classified by lineage (myeloid vs lymphoid), by the stage of maturation at which transformation occurs, and increasingly by defining molecular and cytogenetic lesions, as codified in the World Health Organization classifications (Arber et al., 2016; Swerdlow et al., 2016). Some of these lesions are directly druggable: the BCR-ABL fusion that defines chronic myeloid leukemia is targeted by tyrosine-kinase inhibition, a landmark demonstration that a single molecular driver can be blocked therapeutically (Druker et al., 2001).

Clinical relevance

Blood cancers illustrate how cancer classification can be built on cell lineage and genetics rather than anatomic site, and how identifying molecular drivers and immune targets translates into therapy. This entry describes that framework and its evidence; it does not provide individualized diagnostic or treatment recommendations.

Epidemiology

Collectively the leukemias, lymphomas, and myeloma account for a substantial share of cancer diagnoses and deaths, with incidence varying by subtype, age, and sex; some subtypes predominate in children while others, such as many lymphomas and myeloma, increase with age. Subtype-specific epidemiology is summarized within the standardized classifications and disease-specific guidelines (Arber et al., 2016; Dohner et al., 2017).

Evidence & guidelines

Standardized WHO classifications define disease entities and underpin diagnosis and clinical trials (Arber et al., 2016; Swerdlow et al., 2016), and expert consensus recommendations such as the European LeukemiaNet guidance structure the management of acute myeloid leukemia (Dohner et al., 2017). Randomized trials have established targeted and immune-based regimens across subtypes, including antibody-based combinations in multiple myeloma (Facon et al., 2019); guideline specifics evolve and should be read in current sources.

History

Hematologic malignancies have repeatedly been proving grounds for oncology. The identification of the Philadelphia chromosome and the BCR-ABL fusion in chronic myeloid leukemia, followed by the success of targeted tyrosine-kinase inhibition (Druker et al., 2001), established the model of molecularly targeted cancer therapy. Successive WHO classifications integrated morphology, immunophenotype, and genetics into a unified diagnostic framework that continues to be revised (Arber et al., 2016; Swerdlow et al., 2016).

Seminal works

druker-2001
arber-2016
swerdlow-2016
dohner-2017

Frequently asked questions

What are the main types of hematologic malignancy?: They are broadly the leukemias (cancers of blood-forming cells), the lymphomas (cancers of lymphoid tissue, divided into Hodgkin and non-Hodgkin types), and plasma-cell neoplasms such as multiple myeloma; each is further classified by lineage and genetics.
Why are blood cancers classified by genetics rather than location?: Because they arise from blood and lymphoid cells that circulate or are widely distributed, anatomic site is less informative than cell lineage and defining molecular or cytogenetic changes, which is what standardized classifications use to define disease entities.